Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function.
Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S, Leung L, Vaknin I, Kumar S, Dassa L, Hansen K, Bernados D, Murter B, Soni A, Taube JM, Fader AN, Wang TL, Shih IM, White M, Pardoll DM, Liang SC. Whelan S, et al. Among authors: ophir e. Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18. Cancer Immunol Res. 2019. PMID: 30659054 Free PMC article.
Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity.
Murter B, Pan X, Ophir E, Alteber Z, Azulay M, Sen R, Levy O, Dassa L, Vaknin I, Fridman-Kfir T, Salomon R, Ravet A, Tam A, Levin D, Vaknin Y, Tatirovsky E, Machlenkin A, Pardoll D, Ganguly S. Murter B, et al. Among authors: ophir e. Cancer Immunol Res. 2019 Feb;7(2):244-256. doi: 10.1158/2326-6066.CIR-18-0460. Epub 2019 Jan 18. Cancer Immunol Res. 2019. PMID: 30659055 Free PMC article.
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis.
Alteber Z, Kotturi MF, Whelan S, Ganguly S, Weyl E, Pardoll DM, Hunter J, Ophir E. Alteber Z, et al. Among authors: ophir e. Cancer Discov. 2021 May;11(5):1040-1051. doi: 10.1158/2159-8290.CD-20-1248. Epub 2021 Mar 9. Cancer Discov. 2021. PMID: 33687987 Review.
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, Drake A, Tang M, Wall P, Bernados D, Leung L, Ophir E, Alteber Z, Cojocaru G, Galperin M, Frenkel M, White M, Hunter J, Liang SC, Kotturi MF. Hansen K, et al. Among authors: ophir e. Cancer Immunol Immunother. 2021 Dec;70(12):3525-3540. doi: 10.1007/s00262-021-02921-8. Epub 2021 Apr 26. Cancer Immunol Immunother. 2021. PMID: 33903974 Free PMC article.
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects.
Menachem A, Alteber Z, Cojocaru G, Fridman Kfir T, Blat D, Leiderman O, Galperin M, Sever L, Cohen N, Cohen K, Granit RZ, Vols S, Frenkel M, Soffer L, Meyer K, Menachem K, Galon Tilleman H, Morein D, Borukhov I, Toporik A, Perpinial Shahor M, Tatirovsky E, Mizrachi A, Levy-Barda A, Sadot E, Strenov Y, Eitan R, Jakobson-Setton A, Yanichkin N, Ferre P, Ophir E. Menachem A, et al. Among authors: ophir e. Cancer Immunol Res. 2024 Apr 1:OF1-OF17. doi: 10.1158/2326-6066.CIR-23-0706. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38592331
85 results